A concise review of the current knowledge of osteoporosis, aimed at the busy pratitioner who is increasingly involved in the management of osteoporosis and who wants accurate and practical answers to questions that arise in daily clinical practice. All the major aspects are covered including diagnosis, fractures, prevention and treatment. Each chapter has been written by a recognised expert in the field to provide readers with the most up-to-date and authoritative knowledge on each of the topics discussed, making this an invaluable source of reference.

Osteoporosis, a growing epidemic among women in North America, Europe, and Japan, is a painful, costly disease that has presented a treatment challenge to healthcare professionals. Until recently, therapies have focused on agents that slow bone resorption, and have had only limited success at increasing bone mass. However, exciting new developments are on the verge of changing the treatment of this debilitating disorder. Two anabolic agents, the parathyroid hormone (PTH) and the fluoride ion, show tremendous promise as tools for building and retaining bone - with no adverse side effects. Anabolic Treatments for Osteoporosis is a comprehensive account of the latest studies that have been carried out on these two agents, and a thorough assessment of their prospects as osteoporosis therapeutics. This unique book combines basic science and up-to-date clinical data to present a complete picture of this breakthrough in the treatment of a globally significant health issue.

Providing a comprehensive review of short-and long-term adverse events of both antiresorptive and anabolic drugs, this practical guide updates the clinician on the pathophysiology of osteoporosis and the principles behind our present and future pharmaceuticals. Leading practitioners in the field examine all current literature and data regarding the duration and safety of these therapies, with recommendations for clinicians on decision-making and best practices for osteoporosis patients. An overview of the pathophysiology and epidemiology of osteoporosis and discussion of both anabolic and antiresorptive drugs is followed by fracture risk assessment and an examination of treatment failures. Next, a number of chapters are dedicated to the diagnosis, presentation and management of atypical femur fractures and osteonecrosis of the jaw (ONJ), each of which are significant patient concerns when using these osteoporosis treatments. The introduction and utilization of drug holidays is also discussed, as well as the long-term outlook for management of osteoporotic patients. Written and edited by experts in the field, The Duration and Safety of Osteoporosis Treatment is a balanced resource for researchers, practitioners and policy-makers alike for clinical decision-making and patient care.

The Aging Skeleton is a comprehensive and timely book on all aspects of the skeleton as it ages, including basic mechanisms and pathways as well as pathobiology. Chapters cover general aspects and models of aging, determinants and maintenance of peak bone mass, mechanisms of age-related bone loss, quantifiable manifestations of age-related bone loss, fractures, and therapeutics. - Covers all aspects of the aging skeleton in one comprehensive volume - Looks at the influence of genetics, nutrition, environment, hormones, and other factors on bone mass - Provides a thorough discussion of fractures, one of the major consequences of the aging skeleton - Reviews current therapeutic approaches and methods - Written by internationally renowned authors and edited by leaders in the field - Is the only book available on this subject

Since the publication of the first edition, the U.S. Surgeon General released the first-ever report on bone health and osteoporosis in October 2004. This report focuses even more attention on the devastating impact osteoporosis has on millions of lives. According to the National Osteoporosis Foundation, 2 million American men have osteoporosis, and another 12 million are at risk for this disease. Yet despite the large number of men affected, the lack of awareness by doctors and their patients puts men at a higher risk that the condition may go undiagnosed and untreated. It is estimated that one-fifth to one-third of all hip fractures occur in men. This second edition brings on board John Bilezikian and Dirk Vanderschueren as editors with Eric Orwoll. The table of contents is more than doubling with 58 planned chapters. The format is larger – 8.5 x 11. This edition of Osteoporosis in Men brings together even more eminent investigators and clinicians to interpret developments in this growing field, and describe state-of-the-art research as well as practical approaches to diagnosis, prevention and therapy. - Brings together more eminent investigators and clinicians to interpret developments in this growing field - Describes state-of-the-art research as well as practical approaches to diagnosis, prevention and therapy - There is no book on the market that covers osteoporosis in men as comprehensively as this book

This book provides a practical overview of osteoporosis for the wide spectrum of clinicians that might encounter the osteoporotic patient. Concise and well-structured chapters examine the public health importance of the condition, the current treatment gap, how to identify individuals who would benefit from treatment, bone turnover and how this can be modified by osteoporosis therapies, adjuvant lifestyle modification, the calcium and vitamin D story, antiresorptive therapies, anabolic therapies, emerging therapies, adherence and compliance with therapy and the perception of fracture risk. Osteoporosis Treatment: A Clinical Overview meets the need for a book that improves awareness of this major public health problem and possible therapeutic approaches. Primary care physicians, endocrinologists, rheumatologists, orthopaedic surgeons and those providing specialist care for the elderly will all benefit from this highly accessible and informative guide to treating osteoporosis.

This book provides a review of the most recent data on osteoporosis and bone health, presenting a vision of diagnosis and management for the year 2021 and beyond. It covers all pertinent aspects of bone health including diagnosis, fracture prevention, optimized practice, impaired orthostasis, and falls. The book examines recent developments in therapeutics, including goal-directed therapy, individualizing therapy, sequential and combined therapies, pharmaceuticals, and anabolic vs. antiresorptive therapy. In addition, it provides an in-depth overview of osteoporosis and bone health in complex patients, covering Duchene dystrophy, renal failure, periodontal diseases, and steroid-induced osteoporosis as well as considerations for pediatric populations and men. New Horizons in Osteoporosis Management is an essential resource for physicians and related professionals, residents, fellows, graduate students and nurses in rheumatology, endocrinology, radiology, pediatrics, primary care, and internal medicine.